AstreAdept®: Revolutionizing Cell and Gene Therapy Purification

For over thirty years, Astrea Biosparations has led the way in offering adaptable purification solutions, spanning from process development to commercialization. We are harnessing our expertise to deliver innovations that are advancing cell and gene therapy therapeutic development.

Cell and gene therapy modalities are magnitudes larger than small molecule or recombinant protein-based therapies. Existing technologies fall short for modalities such as lentiviral vectors, exosomes, or plasmids. Our commitment to innovation has led us to develop AstreAdept®, a technology specifically designed to address the unique challenges of cell and gene therapy development, ensuring high productivity for downstream applications. The electrospun technology forms an open network with a large surface area that is highly accessible to viral vectors even at very fast flow rates, unlike traditional resin-based adsorbents.

LentiHERO®, a pre-packed capsule powered by the AstreAdept® technology has been aiding lentiviral vector developers to increase yield, scale processes and reduce loss of LVV during purification.

Increase yield: Lentiviral vector loss occurs due to salt sensitivity resulting in high lentiviral vector aggregation. The unique properties of the AstreAdept® technology requires 50% less salt for elution over traditional strong AEX binding chemistries. This provides a gentler process for fragile LVV particles, resulting in higher functional yields. Additionally, the volume required to dilute the elution pool is reduced, meaning subsequent process step can proceed faster with smaller total volumes.

Scale processes: To be representative at scale, our capsules are in a consistent radial format, allowing scaling to be achieved with precision, starting with a 1 ml adsorbent bed volume, offering high recovery and excellent impurity removal.

Reduce Lentiviral vector loss: A low-shear environment enables high process step recovery of LVV, as the  wide flowpath that is designed for large and fragile modalities LVV damage is prevented, resulting in more LVV from each feedstock batch.

Higher recovery diminishes the need to expand upstream production, thereby allowing for increased productivity in existing facilities. This, coupled with enhanced capacity and quicker process runs, enables the minimization of bioprocessing equipment size, leading to favorable impacts on process economics.

AstreAdept® is poised to revolutionize the market, enabling our clients to expedite their time to clinic, and reach patients faster. Our ambition extends to scaling AstreAdept® for manufacturing, offering comprehensive support from process development through to commercialization, reinforcing our dedication to innovation and customer success.

https://www.astreabioseparations.com/en/